Date: 2014-08-19
Type of information: IPO
Company: Auris Medical (Switzerland)
Investors:
Amount: $60.7 million
Funding type: IPO
Planned used: Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing earlystage research and development projects.
Others: * On August 19, 2014, Auris Medical announced that the underwriters of its initial public offering have exercised their over-allotment option to purchase an additional 713,235 shares of common stock. This option yields the company additional gross proceeds of $4.28 million, or $3.98 million less underwriting discounts, and increases the company's number of outstanding shares to 28,954,510. Auris previously announced the closing of its initial public offering of 9,400,000 of its common shares at a price of $6.00 per common share on August 11, 2014. The company's common shares were approved for listing on the NASDAQ Global Market and began trading under the symbol "EARS" on August 6, 2014. * On August 11, 2014, Auris Medical Holding AG announced the closing of its initial public offering of 9,400,000 of its common shares at an initial public offering price of $ 6.00 per common share. In addition, Auris Medical granted the underwriters a 30-day option from August 5, 2014 to purchase up to an additional 1,410,000 common shares at the public offering price, less underwriting discounts. Auris’ common shares were approved for listing on the NASDAQ Global Market and began trading under the symbol “EARS” on August 6, 2014. * On August 5, 2014, Auris Medical announced the pricing of its initial public offering of 9,400,000 of its common shares at an initial public offering price of $ 6.00 per common share. In addition, Auris Medical has granted the underwriters an option to purchase up to 1,410,000 additional common shares at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the initial public offering are expected to be approximately $ 51 million. The offering is expected to close on or about August 11, 2014, subject to customary closing conditions. Auris Medical's common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol "EARS" on August 6, 2014. * On July 21, 2014, Auris Medical announced that it has commenced the underwritten initial public offering of 6.9 million of its common shares pursuant to a registration statement on Form F-1 with the Securities and Exchange Commission (SEC). In connection with the Offering, the Company intends to grant the underwriters the option to purchase up to 1,035,000 additional common shares. The estimated price range for the initial public offering is $10.00 to $12.00 per common share. Auris Medical Holding AG has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol “EARS”. Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers in the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers in the proposed offering.
Therapeutic area: Otorhinolaryngology
